Resolution of new daily persistent headache by a tumor necrosis factor alpha antagonist, Venlafaxine.

Clicks: 446
ID: 61286
2019
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
New daily persistent headache is a continuous, unremitting headache, notorious for its unresponsiveness to aggressive medical interventions. The underlying pathophysiology of new daily persistent headache is poorly understood resulting in unending, chronic pain. However, a prior study identified elevated tumor necrosis factor alpha within the cerebral spinal fluid of new daily persistent headache patients. Herein, we report on a patient who suffered with headache for 6 years failing to respond to over 20 different medical treatments, but found drastic improvement and eventual resolution with Venlafaxine. This drug binds to the 5-HT receptor inhibiting tumor necrosis factor alpha signaling. Therefore, we hypothesize a chronic inflammatory mechanism driving new daily persistent headache pathology.
Reference Key
tariq2019resolutionsage Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Tariq, Zeshan;Board, Nathan;Eftimiades, Alex;Ibrahim, Ronnie;
Journal sage open medical case reports
Year 2019
DOI
10.1177/2050313X19847804
URL
Keywords
serotonin headache venlafaxine 5ht-2a ndph new daily persistent headache tnf-alpha tumor necrosis factor alpha

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.